MEET THE GUEST EDITOR [Hot Topic: Modern Omics-Based Platform for High Throughput Screening for Novel Drug Targets (Part 2) (Guest Editor: Canhua Huang)]

Canhua      Huang

doi:10.2174/138620712799361870

Abstract

BIOGRAPHY Prof. Canhua Huang obtained his Ph.D. in Academia Sinica in 2000 and after postdoctoral training at Department of Biological Sciences, National University of Singapore, he was appointed as Research Scientist in Oncology Research Institute, NUS (2003-2005). In Sept 2005, he joined in the State Key Lab of Biotherapy, West China Hospital, Sichuan University, leading a group for oncoproteomics research. RESEARCH INTEREST • High throughput System Biology screening novel drug targets for anti-cancer research. • Mechanisms of virus-induced carcinogenesis; Cancer metabolics and epigenetics. • Chemistry-based functional proteomics for novel drug target deconvolution. SELECTED RECENT PUBLICATIONS [1] Lei, Y.; Huang, K.; Gao, C.; Lau, Q.C.; Pan, H.; Xie, K.; Li, J.; Liu, R.; Zhang, T.; Xie, N.; Nai, H.S.; Wu, H.; Dong, Q.; Zhao, X.; Nice, E.C.; Huang, C.; Wei. Y. Proteomics identification of ITGB3 as a key regulator in ROS-induced migration and invasion of colorectal cancer cells. Mol. Cell Proteomics, 2011, 10(10), M110.005397. [2] Xie, N.; Huang, K.; Zhang, T.; Huang, K.; Lei, Y.; Wu, H.; Zhao, X.; Nice, E.; Huang, C. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection. J. Proteomics, 2012, 75 (3), 725-739. [3] Yuan, K.; Huang, C.; Fox, J.; Gaid, M.; Weaver, A.; Li, G.P.; Singh, B.B.; Gao, H.; Wu, M. Elevated inflammatory response in Caveolin-1 deficient mice with P. aeruginosa infection is mediated by STAT3 and NF-{kappa}B. J. Biol. Chem., 2011, 286(24), 21814-21825. [4] Wang, K.; Liu, R.; Li, J.; Mao, J.; Xie, N.; Wu, J.; Lei, Y.; Zhang, T.; Zeng, J.; Wu, H.; Chen, L.; Huang, C.; Wei, Y. Quercetin induces protective autophagy in gastric cancer cells: Involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Autophagy, 2011, 7(9), 966-978. [5] Hu, H.; Deng, C.; Dong, Q.; Yang, T.; Chen, Y.; Huang, C.; Wei, Y. Proteomics revisits the cancer metabolome. Expert Rev. Proteomics, 2011, 8(4), 505-533. [6] Li, J.; Liu, R.; Lei, Y.; Wang, K.; Lau, Q.C.; Xie, N.; Zhou, S.; Nie, C.; Chen, L.; Wei, Y.; Huang, C. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy, 2010, 6 (6), 711-724. [7] Liu, R.; Wang, K.; Yuan, K.; Wei, Y.; Huang, C. Integrative oncoproteomics strategies for anti-cancer drug discovery. Expert Rev. Proteomics, 2010, 7(3), 411- 429. [8] Yuan, K.; Lei, Y.; Huang, C. Application of chemistry-based functional proteomics to screening for novel drug targets. Comb. Chem. High Throughput Screen., 13 (5), 414-421. [9] Ren, F.; Wu, H.; Lei, Y.; Zhang, H.; Liu, R.; Zhao, Y.; Chen, X.; Zeng, D.; Tong, A.; Chen, L.; Wei, Y.; Huang, C. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol. Cancer, 2010, 9, 81. [10] Liu, R.; Li, Z.; Bai, S.; Zhang, H.; Tang, M.; Lei, Y.; Chen, L.; Liang, S.; Zhao, Y.; Wei, Y.; Huang, C. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone mediated gastric carcinogenic signaling pathway. Mol. Cell Proteomics, 2009, 8(1), 70-85. [11] Li, Z.; Zhao, X.; Bai, S.; Wang. Z.; Chen, L.; Wei, Y.; Huang, C. Proteomic identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol. Cell Proteomics, 2008, 7(10), 1810-1823. [12] Wang, Z.; Jiang, L.; Huang, C.; Li, Z.; Tong, A.; Chen, L.; Shen, J.; Gao, F.; Chen, Q. Comparative proteomic approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol. Cell Proteomics, 2008, 7, 1639-1650. [13] Tong, A.; Gou, L.; Lau, Q.; Li, J.; Zhao, X.; Chen, L.; Tang, H.; Huang, C.; Wei Y. Proteomic Profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J. Proteome Res., 2009, 8(2), 1037-1046. [14] Tong, A.; Wu, L.; Lin, Q.; Lau, Q.; Li, J.; Chen, L.; Tang, H.; Huang, C.; Wei, Y. Proteomic analysis of cellular protein alterations using a HBV-producing cellular model. Proteomics 2008, 8, 2012-2023. [15] Li, Z.; Huang, C.; Bai, S.; Pan, X.;, Zhou, R.; Wei, Y.; Zhao, X. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int. J. Cancer, 2008, 123 (10), 2377-2383. [16] Shen, J.; Huang, C.; Jiang, L.; Gao, F.; Wang, Z.; Zhang, Y.; Bai, J.; Chen, Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol., 2007, 73(12), 1901-1909. [17] Huang, C.; Ida, H.; Ito, K.; Zhang, H.; Ito, Y. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem. Pharmacol.,2007, 73(7), 990-1000. [18] Tong, A.; Zhang, H.; Li, Z.; Gou, L.; Wang, Z.; Wei, H.; Tang, M.; Liang, S.; Chen, L.; Huang, C.; Wei, Y. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother. Pharmacol., 2008, 61(5),791-802. [19] Zhou, S.; Liu, R.; Zhao, X.; Huang, C.; Wei, Y. Viral Proteomics: the emerging cutting edge of virus research. Sci. China Life Sci., 2011, 54(6), 502-512.

« Previous Next »